LUMO vs. EQ, NXTC, KZR, CARM, LSB, NBRV, MRKR, CALC, BTAI, and FBIO
Should you be buying Lumos Pharma stock or one of its competitors? The main competitors of Lumos Pharma include Equillium (EQ), NextCure (NXTC), Kezar Life Sciences (KZR), Carisma Therapeutics (CARM), Lakeshore Biopharma (LSB), Nabriva Therapeutics (NBRV), Marker Therapeutics (MRKR), CalciMedica (CALC), BioXcel Therapeutics (BTAI), and Fortress Biotech (FBIO). These companies are all part of the "pharmaceutical preparations" industry.
Equillium (NASDAQ:EQ) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, community ranking, institutional ownership and dividends.
Equillium has higher revenue and earnings than Lumos Pharma. Equillium is trading at a lower price-to-earnings ratio than Lumos Pharma, indicating that it is currently the more affordable of the two stocks.
Equillium received 1 more outperform votes than Lumos Pharma when rated by MarketBeat users. Likewise, 83.33% of users gave Equillium an outperform vote while only 77.27% of users gave Lumos Pharma an outperform vote.
In the previous week, Lumos Pharma had 3 more articles in the media than Equillium. MarketBeat recorded 5 mentions for Lumos Pharma and 2 mentions for Equillium. Lumos Pharma's average media sentiment score of 0.96 beat Equillium's score of 0.27 indicating that Equillium is being referred to more favorably in the media.
27.1% of Equillium shares are owned by institutional investors. Comparatively, 34.0% of Lumos Pharma shares are owned by institutional investors. 30.3% of Equillium shares are owned by insiders. Comparatively, 25.4% of Lumos Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Equillium has a net margin of -32.01% compared to Equillium's net margin of -2,434.69%. Lumos Pharma's return on equity of -51.20% beat Equillium's return on equity.
Equillium presently has a consensus target price of $3.90, suggesting a potential upside of 376.95%. Lumos Pharma has a consensus target price of $18.00, suggesting a potential upside of 900.00%. Given Equillium's higher possible upside, analysts clearly believe Lumos Pharma is more favorable than Equillium.
Equillium has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500.
Summary
Equillium beats Lumos Pharma on 11 of the 17 factors compared between the two stocks.
Get Lumos Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LUMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lumos Pharma Competitors List
Related Companies and Tools
Free LUMO Stock Alerts